pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 493
- Drugs
- 98
- Patents
- 837
Quick answer
Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degeneration, Melanoma. NovaPharmaNews links 493 clinical program(s), 8 drug profile(s), and 837 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (176), phase 3 (129), phase 1 (126).
Company snapshot
Regeneron UK maintains 493 tracked programs across Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degeneration, Melanoma, Atopic Dermatitis, COVID-19, Chronic Obstructive Pulmonary Disease, Paroxysmal Nocturnal Hemoglobinuria, Neovascular Age-Related Macular Degeneration, Prostate Cancer, Non-small Cell Lung Cancer. Momentum score: 35/100 (30-day delta: n/a). Public registry data co
- 10 approved product(s) across US/EU regulatory metadata.
- 493 active pipeline program(s) linked via ClinicalTrials.gov.
- 837 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Regeneron UK. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
Regeneron Immunotherapy Combo Fails in Melanoma Trial
- deal
Regeneron Secures $125M Parabilis Deal for Drug Targets
- deal
Parabilis IPO Plans Following Regeneron Deal: What You Need to Know
- approval
Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights
- approval
Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment
- approval
FDA approves Dupixent for COPD with eosinophilic phenotype
- approval
Sensorion pivots to SENS-601 after Regeneron’s OTOF hearing loss advance
Recent coverage
Sensorion pivots to SENS-601 after Regeneron’s OTOF hearing loss advance
Sensorion has redirected its hearing-loss strategy after Regeneron’s Otarmeni became the first and only FDA-approved in vivo gene therapy for OTOF-related hearing loss. The move underscores a widening split between rare OTOF programs and broader GJB2-targeted opportunities.
FDA approves Dupixent for COPD with eosinophilic phenotype
The FDA has approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. The decision gives Regeneron and Sanofi a new regulatory catalyst to track for commercial and investor implications.
Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment
Regeneron Pharmaceuticals' stock shows resilience despite a recent analyst price target reduction and ongoing European Medicines Agency (EMA) review of an eye drug. The market appears to be absorbing these developments without significant share price volatility.
Parabilis IPO Plans Following Regeneron Deal: What You Need to Know
Parabilis has announced its IPO plans just a day after the Regeneron deal, signaling a surge in listings. This article explores the implications for the pharmaceutical landscape.
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Regeneron UK.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Regeneron UK.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Regeneron UK?
-
Is Regeneron UK publicly traded?
-
What drugs does Regeneron UK develop or market?
-
What are the latest developments for Regeneron UK?
-
What therapeutic areas does Regeneron UK focus on?
Full intelligence profile
Registry synthesis
Grounded overview from trials, patents, coverage, and catalysts.
Regeneron UK maintains 493 tracked programs across Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degeneration, Melanoma, Atopic Dermatitis, COVID-19, Chronic Obstructive Pulmonary Disease, Paroxysmal Nocturnal Hemoglobinuria, Neovascular Age-Related Macular Degeneration, Prostate Cancer, Non-small Cell Lung Cancer. Momentum score: 35/100 (30-day delta: n/a).
Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial coverage. HQ: Tarrytown USA. Ticker: REGN.
Pipeline programs
Cemiplimab — phase phase_3, status active. Indication: Recurrent Lung Non-Small Cell Carcinoma. Next milestone: not disclosed (TBD).
Intravitreal Aflibercept Injection (IAI) — phase phase_3, status completed. Indication: Proliferative Diabetic Retinopathy. Next milestone: not disclosed (TBD).
Cemiplimab — phase phase_3, status active. Indication: Cutaneous Squamous Cell Carcinoma (CSCC). Next milestone: not disclosed (TBD).
cemiplimab — phase phase_3, status active. Indication: Non-small Cell Lung Cancer. Next milestone: not disclosed (TBD).
Atorvastatin — phase phase_3, status completed. Indication: Hypercholesterolemia. Next milestone: not disclosed (TBD).
Dupilumab SAR231893 — phase phase_3, status completed. Indication: Chronic Spontaneous Urticaria. Next milestone: not disclosed (TBD).
Alirocumab — phase phase_3, status completed. Indication: Homozygous Familial Hypercholesterolemia. Next milestone: not disclosed (TBD).
casirivimab+imdevimab combination therapy — phase phase_3, status terminated. Indication: COVID-19. Next milestone: not disclosed (TBD).
EFC6125 — phase phase_3, status completed. Indication: Ovarian Neoplasms. Next milestone: not disclosed (TBD).
EFC10261 — phase phase_3, status completed. Indication: Carcinoma. Next milestone: not disclosed (TBD).
13406 — phase phase_3, status completed. Indication: Macular Degeneration. Next milestone: not disclosed (TBD).
REGN3918 — phase phase_3, status terminated. Indication: Paroxysmal Nocturnal Hemoglobinuria. Next milestone: not disclosed (TBD).
Recent Nova coverage
Nova coverage: Sensorion pivots to SENS-601 after Regeneron’s OTOF hearing loss advance (2026-06-11).
Nova coverage: FDA approves Dupixent for COPD with eosinophilic phenotype (2026-06-07).
Nova coverage: Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment (2026-06-02).
Nova coverage: Parabilis IPO Plans Following Regeneron Deal: What You Need to Know (2026-05-21).
Nova coverage: Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights (2026-05-21).
Nova coverage: Regeneron's Phase 3 Skin Cancer Trial Failure: Implications for LAG-3 (2026-05-19).
Nova coverage: Regeneron Secures $125M Parabilis Deal for Drug Targets (2026-05-19).
Nova coverage: Regeneron's Phase 3 Skin Cancer Miss: Implications for LAG-3 Development (2026-05-19).
Registry facts
Registry profile: founded unknown; employees 16715; market cap n/a; revenue n/a; LEI n/a; CIK 0000872589.
Company type: pharma; public/private: public. Data quality score: 0.864.
Catalyst calendar
Catalyst: Regeneron Immunotherapy Combo Fails in Melanoma Trial — type trial_data, date 2026-05-18.
Catalyst: Regeneron Secures $125M Parabilis Deal for Drug Targets — type deal, date 2026-05-19.
Catalyst: Parabilis IPO Plans Following Regeneron Deal: What You Need to Know — type deal, date 2026-05-21.
Catalyst: Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights — type approval, date 2026-05-21.
Catalyst: Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment — type approval, date 2026-06-02.
Catalyst: FDA approves Dupixent for COPD with eosinophilic phenotype — type approval, date 2026-06-07.
Catalyst: Sensorion pivots to SENS-601 after Regeneron’s OTOF hearing loss advance — type approval, date 2026-06-11.
Competitive peers
Peer: Novartis India (overlap score 50.0).
Peer: AstraZeneca (overlap score 50.0).
Peer: Sanofi-Aventis U.S (overlap score 40.0).
Peer: United Therapeutics Europe (overlap score 40.0).
Peer: First People's Hospital (overlap score 40.0).
Peer: Sanofi Pasteur MSD (overlap score 36.6).
Peer: MedImmune (overlap score 31.8).
Peer: Nektar Therapeutics UK (overlap score 31.4).
Competitive positioning reflects therapeutic-area overlap with peer sponsors and recent catalyst activity from trials, regulatory actions, and congress presentations. Data is assembled from ClinicalTrials.gov, SEC EDGAR, openFDA, and NovaPharmaNews articles — not third-party wire republication.
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.